Department of Pathology, Guangdong Medical University, Dongguan, China; Center of Pathology Diagnosis and Research, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Department of Oncology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Biomed Pharmacother. 2020 Nov;131:110775. doi: 10.1016/j.biopha.2020.110775. Epub 2020 Sep 26.
Lung cancer is a malignant tumor that seriously threatens human life and health. Non-small cell lung cancer (NSCLC) accounts for 85 % of all lung cancer cases, and its global 5-year survival rate is only approximately 5%. Thus, the identification of new prognostic biomarkers has become one of the most urgent challenges in NSCLC research. Long noncoding RNAs (LncRNAs) are a kind of noncoding RNA whose length exceeds 200 nucleotides (nt). LncRNAs are transcribed by RNA pol II and can be subjected to posttranscriptional modifications such as blocking, polyadenylation and splicing; moreover, their expression profiles are more specific than those of mRNAs. Emerging evidence confirms that lncRNAs are associated with the occurrence and development of NSCLC and play an important role in NSCLC drug resistance. The purpose of this review was to describe the roles of lncRNAs in the development, diagnosis and prognosis of NSCLC and to explore new evidence of lncRNAs in the treatment of NSCLC drug resistance. This review provides a new perspective of lncRNAs in the treatment of NSCLC.
肺癌是严重威胁人类生命健康的恶性肿瘤。非小细胞肺癌（NSCLC）占所有肺癌病例的 85%，其全球 5 年生存率仅约为 5%。因此，寻找新的预后生物标志物已成为 NSCLC 研究中最紧迫的挑战之一。长链非编码 RNA（lncRNA）是一类长度超过 200 个核苷酸（nt）的非编码 RNA。lncRNA 由 RNA pol II 转录，可以进行阻断、多聚腺苷酸化和剪接等转录后修饰；此外，其表达谱比 mRNAs 更具特异性。越来越多的证据证实，lncRNAs 与 NSCLC 的发生发展有关，并在 NSCLC 耐药中发挥重要作用。本文旨在描述 lncRNAs 在 NSCLC 发生、诊断和预后中的作用，并探讨 lncRNAs 在 NSCLC 耐药治疗中的新证据。本文为 lncRNAs 在 NSCLC 治疗中的应用提供了新视角。
